- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Most Popular Stocks
U.S. Pharmaceuticals & Biotech Most Popular Stocks
Results
1140
Most Popular Stocks on the market
1140 companies
Atai Life Sciences
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
ATAI
US$5.17
7D
9.5%
1Y
334.5%
LENZ Therapeutics
Market Cap: US$1.2b
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$40.03
7D
-4.0%
1Y
79.9%
Pacira BioSciences
Market Cap: US$1.2b
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
PCRX
US$25.65
7D
-3.8%
1Y
79.0%
Dynavax Technologies
Market Cap: US$1.2b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$9.73
7D
-0.2%
1Y
-10.3%
BioLife Solutions
Market Cap: US$1.2b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$24.18
7D
-8.0%
1Y
0.04%
Precigen
Market Cap: US$1.2b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$3.49
7D
-8.3%
1Y
282.0%
Maze Therapeutics
Market Cap: US$1.1b
A clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
MAZE
US$26.35
7D
12.2%
1Y
n/a
Nektar Therapeutics
Market Cap: US$1.1b
A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
NKTR
US$55.62
7D
-5.3%
1Y
234.1%
Enliven Therapeutics
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
ELVN
US$18.57
7D
-6.8%
1Y
-23.0%
Nuvation Bio
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
NUVB
US$3.01
7D
-5.0%
1Y
21.9%
Collegium Pharmaceutical
Market Cap: US$1.1b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$34.65
7D
-4.2%
1Y
-9.9%
Wave Life Sciences
Market Cap: US$1.1b
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
WVE
US$6.66
7D
-4.3%
1Y
-17.0%
MiMedx Group
Market Cap: US$1.0b
Develops and distributes placental tissue allografts for various sectors of healthcare.
MDXG
US$6.98
7D
-2.4%
1Y
23.5%
Praxis Precision Medicines
Market Cap: US$1.0b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$49.25
7D
8.9%
1Y
-14.8%
Trevi Therapeutics
Market Cap: US$1.0b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$8.46
7D
3.8%
1Y
154.1%
Spyre Therapeutics
Market Cap: US$1.0b
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
SYRE
US$15.61
7D
1.9%
1Y
-46.3%
ORIC Pharmaceuticals
Market Cap: US$1.0b
A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.
ORIC
US$10.41
7D
-5.4%
1Y
0.5%
BridgeBio Oncology Therapeutics
Market Cap: US$983.8m
A clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies.
BBOT
US$11.82
7D
9.2%
1Y
13.1%
Immunome
Market Cap: US$974.9m
A clinical-stage biotechnology company, develops targeted cancer therapies.
IMNM
US$10.16
7D
3.1%
1Y
-29.2%
EyePoint Pharmaceuticals
Market Cap: US$970.5m
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
EYPT
US$13.19
7D
-4.1%
1Y
63.4%
ARS Pharmaceuticals
Market Cap: US$951.7m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$9.54
7D
-3.9%
1Y
-34.3%
Oculis Holding
Market Cap: US$927.4m
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.
OCS
US$17.50
7D
0.6%
1Y
44.4%
Upstream Bio
Market Cap: US$903.0m
A clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
UPB
US$16.31
7D
-5.6%
1Y
n/a
Sana Biotechnology
Market Cap: US$893.6m
A biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
SANA
US$3.39
7D
3.0%
1Y
-20.6%
Immatics
Market Cap: US$891.0m
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
IMTX
US$7.05
7D
6.7%
1Y
-39.9%
CorMedix
Market Cap: US$877.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$11.12
7D
-4.9%
1Y
35.1%
Tango Therapeutics
Market Cap: US$867.8m
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
TNGX
US$7.97
7D
1.3%
1Y
8.3%
GH Research
Market Cap: US$862.8m
Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.
GHRS
US$13.40
7D
1.4%
1Y
91.4%
Arbutus Biopharma
Market Cap: US$860.7m
A clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
ABUS
US$4.32
7D
-2.3%
1Y
9.1%
Fortrea Holdings
Market Cap: US$859.9m
A contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
FTRE
US$8.92
7D
-16.2%
1Y
-54.9%
Taysha Gene Therapies
Market Cap: US$859.3m
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
TSHA
US$3.06
7D
2.3%
1Y
45.7%
Zenas BioPharma
Market Cap: US$854.0m
A clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
ZBIO
US$18.62
7D
-4.3%
1Y
7.7%
Geron
Market Cap: US$848.6m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.27
7D
-3.8%
1Y
-71.3%
UroGen Pharma
Market Cap: US$832.3m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$17.26
7D
-8.5%
1Y
35.4%
Kodiak Sciences
Market Cap: US$816.4m
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
KOD
US$15.68
7D
59.3%
1Y
478.6%
Phathom Pharmaceuticals
Market Cap: US$815.6m
A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
PHAT
US$11.66
7D
-0.8%
1Y
-34.6%